NasdaqGS - Delayed Quote USD
Terns Pharmaceuticals, Inc. (TERN)
3.4950
+0.2150
+(6.55%)
At close: June 3 at 4:00:01 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | -0.29 | -0.3 | -1.19 | -1.21 |
| Low Estimate | -0.31 | -0.34 | -1.38 | -1.53 |
| High Estimate | -0.27 | -0.28 | -1.1 | -0.75 |
| Year Ago EPS | -0.31 | -0.28 | -1.12 | -1.19 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 8 | 7 |
| Avg. Estimate | -- | -- | -- | 1.37M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 9.6M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.34 | -0.32 | -0.3 | -0.27 |
| EPS Actual | -0.31 | -0.28 | -0.24 | -0.26 |
| Difference | 0.03 | 0.04 | 0.06 | 0.01 |
| Surprise % | 8.74% | 12.91% | 20.05% | 3.79% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.29 | -0.3 | -1.19 | -1.21 |
| 7 Days Ago | -0.29 | -0.3 | -1.17 | -1.28 |
| 30 Days Ago | -0.29 | -0.3 | -1.2 | -1.34 |
| 60 Days Ago | -0.29 | -0.3 | -1.19 | -1.35 |
| 90 Days Ago | -0.33 | -0.34 | -1.32 | -1.39 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 3 | 4 |
| Down Last 7 Days | 1 | 1 | -- | -- |
| Down Last 30 Days | 1 | 1 | 2 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TERN | 6.72% | -7.90% | -6.18% | -1.33% |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.96% |
Upgrades & Downgrades
| Maintains | BMO Capital: Outperform to Outperform | 5/13/2025 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/21/2025 |
| Initiated | William Blair: Market Perform | 2/28/2025 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 12/4/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 12/4/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 12/4/2024 |
Related Tickers
ALT Altimmune, Inc.
5.42
+2.26%
GPCR Structure Therapeutics Inc.
21.97
+0.83%
RLAY Relay Therapeutics, Inc.
3.2900
+3.46%
PRTA Prothena Corporation plc
4.8300
+3.65%
FULC Fulcrum Therapeutics, Inc.
7.04
+1.08%
CRVS Corvus Pharmaceuticals, Inc.
4.1200
+2.23%
AKRO Akero Therapeutics, Inc.
51.61
+1.73%
ATXS Astria Therapeutics, Inc.
4.9600
+3.77%
MTSR Metsera, Inc.
29.35
+4.37%
ETNB 89bio, Inc.
10.17
+0.59%